These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 22338574)
21. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial. Serebruany VL; Midei MG; Meilman H; Malinin AI; Lowry DR Int J Clin Pract; 2006 Jul; 60(7):863-6. PubMed ID: 16846403 [TBL] [Abstract][Full Text] [Related]
22. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Steinhubl SR; Badimon JJ; Bhatt DL; Herbert JM; Lüscher TF Vasc Med; 2007 May; 12(2):113-22. PubMed ID: 17615799 [TBL] [Abstract][Full Text] [Related]
23. Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing. Freynhofer MK; Gruber SC; Grove EL; Weiss TW; Wojta J; Huber K Thromb Haemost; 2015 Aug; 114(3):459-68. PubMed ID: 26272640 [TBL] [Abstract][Full Text] [Related]
25. The role of the platelet in the pathogenesis of atherothrombosis. Steinhubl SR; Moliterno DJ Am J Cardiovasc Drugs; 2005; 5(6):399-408. PubMed ID: 16259528 [TBL] [Abstract][Full Text] [Related]
26. Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. Arif SA; D'Souza J; Gil M; Gim S Am J Health Syst Pharm; 2015 Oct; 72(19):1615-22. PubMed ID: 26386102 [TBL] [Abstract][Full Text] [Related]
27. Alteration of platelet GPVI signaling in ST-elevation myocardial infarction patients demonstrated by a combination of proteomic, biochemical, and functional approaches. Vélez P; Ocaranza-Sánchez R; López-Otero D; Grigorian-Shamagian L; Rosa I; Guitián E; García-Acuña JM; González-Juanatey JR; García Á Sci Rep; 2016 Dec; 6():39603. PubMed ID: 28004756 [TBL] [Abstract][Full Text] [Related]
28. Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. Fintel DJ Vasc Health Risk Manag; 2012; 8():77-89. PubMed ID: 22393298 [TBL] [Abstract][Full Text] [Related]
29. Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar. Cheng JW Vasc Health Risk Manag; 2016; 12():263-8. PubMed ID: 27366081 [TBL] [Abstract][Full Text] [Related]
30. The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke. Goebel S; Li Z; Vogelmann J; Holthoff HP; Degen H; Hermann DM; Gawaz M; Ungerer M; Münch G PLoS One; 2013; 8(7):e66960. PubMed ID: 23935828 [TBL] [Abstract][Full Text] [Related]
31. High residual platelet reactivity (HRPR) for adenosine diphosphate (ADP) stimuli is a determinant factor for long-term outcomes in acute ischemic stroke with anti-platelet agents: The meaning of HRPR after ADP might be more prominent in large atherosclerotic infarction than other subtypes of AIS. Cha JK; Park HS; Nah HW; Kim DH; Kang MJ; Choi JH; Huh JT; Suh HK J Thromb Thrombolysis; 2016 Jul; 42(1):107-17. PubMed ID: 26680778 [TBL] [Abstract][Full Text] [Related]
32. Antiplatelet therapy and vascular disease: an update. Buch MH; Prendergast BD; Storey RF Ther Adv Cardiovasc Dis; 2010 Aug; 4(4):249-75. PubMed ID: 21303843 [TBL] [Abstract][Full Text] [Related]
33. Platelet collagen receptor glycoprotein VI as a possible novel indicator for the acute coronary syndrome. Bigalke B; Geisler T; Stellos K; Langer H; Daub K; Kremmer E; Seizer P; May AE; Lindemann S; Gawaz M Am Heart J; 2008 Jul; 156(1):193-200. PubMed ID: 18585516 [TBL] [Abstract][Full Text] [Related]
34. Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Verdoia M; Pergolini P; Rolla R; Sartori C; Nardin M; Schaffer A; Barbieri L; Daffara V; Marino P; Bellomo G; Suryapranata H; De Luca G; Platelets; 2016 Sep; 27(6):576-82. PubMed ID: 27540959 [TBL] [Abstract][Full Text] [Related]
35. Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs. Harbi MH; Smith CW; Alenazy FO; Nicolson PLR; Tiwari A; Watson SP; Thomas MR Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805988 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Morrow DA; Alberts MJ; Mohr JP; Ameriso SF; Bonaca MP; Goto S; Hankey GJ; Murphy SA; Scirica BM; Braunwald E; Stroke; 2013 Mar; 44(3):691-8. PubMed ID: 23396280 [TBL] [Abstract][Full Text] [Related]
37. Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. Cavallari I; Morrow DA; Creager MA; Olin J; Bhatt DL; Steg PG; Storey RF; Cohen M; Scirica BS; Piazza G; Goodrich EL; Braunwald E; Sabatine MS; Bonaca MP Circulation; 2018 Feb; 137(7):684-692. PubMed ID: 29084737 [TBL] [Abstract][Full Text] [Related]
38. Platelet glycoprotein VI dimerization, an active process inducing receptor competence, is an indicator of platelet reactivity. Loyau S; Dumont B; Ollivier V; Boulaftali Y; Feldman L; Ajzenberg N; Jandrot-Perrus M Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):778-85. PubMed ID: 22155453 [TBL] [Abstract][Full Text] [Related]